Antifungal agents used for deep-seated mycotic infections.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Mayo Clinic proceedings

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/s0025-6196(12)62506-3PMID 3682956
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study.

  2020cited by this paper
• Ketoconazole: A Review of its Therapeutic Efficacy in Superficial and Systemic Fungal Infections

  2012cited by this paper
• Itraconazole for deep mycoses: preliminary experience in Mexico.

  1987cited by this paper
• Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results.

  1987cited by this paper
• Itraconazole in the treatment of human mycoses: review of three years of clinical experience.

  1987cited by this paper
• Itraconazole for cryptococcal infection in the acquired immunodeficiency syndrome.

  1987cited by this paper
• A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis.

  1987cited by this paper
• Itraconazole: pharmacologic studies in animals and humans.

  1987cited by this paper
• Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans.

  1987cited by this paper
• Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies.

  1987cited by this paper
• Ketoconazole-resistant Candida esophagitis in patients with acquired immunodeficiency syndrome.

  1986cited by this paper
• Itraconazole therapy in lymphangitic and cutaneous sporotrichosis.

  1986cited by this paper
• Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment.

  1986cited by this paper
• Ketoconazole therapy for endemic blastomycosis.

  1985cited by this paper
• Successful medical treatment of pulmonary petriellidiosis.

  1985cited by this paper
• Cutaneous, ocular, and osteoarticular candidiasis in heroin addicts: new clinical and therapeutic aspects in 38 patients.

  1985cited by this paper
• Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans

  1985cited by this paper
• Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis.

  1985cited by this paper
• Reversible adrenal insufficiency induced by ketoconazole.

  1985cited by this paper
• Hydrochloric acid given with ketoconazole through a jejunostomy tube.

  1984cited by this paper
• In vitro studies with R 51,211 (itraconazole)

  1984cited by this paper
• Cyclosporine and ketoconazole.

  1984cited by this paper
• Itraconazole, a new triazole that is orally active in aspergillosis

  1984cited by this paper
• Potentiation of oral anticoagulants by ketoconazole.

  1984cited by this paper
• Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases.

  1984cited by this paper
• Treatment of murine pulmonary cryptococcosis with ketoconazole and amphotericin B.

  1984cited by this paper
• Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients.

  1984cited by this paper
• Pseudallescheria boydii infections treated with ketoconazole. Clinical evaluations of seven patients and in vitro susceptibility results.

  1984cited by this paper
• Influence of food on the pharmacokinetics of ketoconazole

  1984cited by this paper
• Ketoconazole.

  1983cited by this paper
• Treatment of paracoccidioidomycosis with ketoconazole: a three-year experience.

  1983cited by this paper
• Laboratory and clinical assessment of ketoconazole in deep-seated mycoses.

  1983cited by this paper
• High-dose ketoconazole for treatment of fungal infections of the central nervous system.

  1983cited by this paper
• Post-therapy status of paracoccidioidomycosis treated with ketoconazole.

  1983cited by this paper
• Miconazole in the Treatment of Coccidioidomycosis

  1983cited by this paper
• Phenytoin intoxication during treatment with parenteral miconazole.

  1983cited by this paper
• Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis.

  1983cited by this paper
• Ketoconazole treatment of Candida esophagitis--a prospective study of 12 cases.

  1983cited by this paper
• Treatment of disseminated and progressive cavitary histoplasmosis with ketoconazole.

  1983cited by this paper
• Effect of ketoconazole on the fungicidal action of amphotericin B in Candida albicans

  1983cited by this paper
• Ketoconazole for treatment of disseminated coccidioidomycosis.

  1982cited by this paper
• Ketoconazole blocks adrenal steroid synthesis.

  1982cited by this paper
• Ketoconazole for treatment of chronic pulmonary coccidioidomycosis.

  1982cited by this paper
• Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients.

  1982cited by this paper
• Failure of ketoconazole in cryptococcal meningitis.

  1982cited by this paper
• Disposition of ketoconazole, an oral antifungal, in humans

  1982cited by this paper
• Impairing effect of food on ketoconazole absorption

  1982cited by this paper
• Progressive disseminated histoplasmosis; favorable response to ketoconazole.

  1981cited by this paper
• Miconazole in cryptococcosis and systemic candidiasis: a word of caution.

  1981cited by this paper
• Liquid chromatographic assay of ketoconazole

  1981cited by this paper
• Treatment of coccidioidomycosis with ketoconazole: clinical and laboratory studies of 18 patients.

  1980cited by this paper
• Chronic mucocutaneous candidosis and other superficial and systemic mycoses successfully treated with ketoconazole.

  1980cited by this paper
• Cardiorespiratory toxicity due to miconazole.

  1980cited by this paper
• Ketoconazole in the treatment of paracoccidioidomycosis and histoplasmosis.

  1980cited by this paper
• The influence of gastric acidity on the bio-availability of ketoconazole.

  1980cited by this paper
• Treatment of coccidioidomycosis with miconazole.

  1980cited by this paper
• In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis

  1980cited by this paper
• An evaluation of two years of clinical experience with ketoconazole.

  1980cited by this paper
• A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis.

  1979cited by this paper
• Deep infections from Petriellidium boydii treated with miconazole.

  1979cited by this paper
• Paracoccidioidomycosis (South American blastomycosis): treatment with miconazole.

  1978cited by this paper
• Flucytosine.

  1977cited by this paper
• Sporotrichosis arthritis: clinical features in seven patients.

  1977cited by this paper
• Miconazole in the treatment of systemic fungal infections.

  1977cited by this paper
• Treatment of fungal meningitis with miconazole.

  1977cited by this paper
• Cryptococcosis, with emphasis on the significance of isolation of Cryptococcus neoformans from the respiratory tract.

  1977cited by this paper
• Synergism of amphotericin B and 5-fluorocytosine for candida species.

  1975cited by this paper
• Therapy of cryptococcosis with a combination of flucytosine and amphotericin B.

  1975cited by this paper
• Endogenous Candida oculomycosis. Report of two patients treated with flucytosine.

  1974cited by this paper
• 5-fluorocytosine: an oral antifungal compound. A report on clinical and laboratory experience.

  1972cited by this paper
• Studies on the biological properties of polyene antibiotics: comparison of other polyenes with filipin in their ability to interact specifically with sterol.

  1972cited by this paper
• Asymptomatic candiduria. Prognosis, complications and some other clinical considerations.

  1972cited by this paper
• 5-fluorocytosine treatment of candida infections of the urinary tract and other sites.

  1972cited by this paper
• Primary renal Candida infection.

  1971cited by this paper
• 5-fluorocytosine in the treatment of cryptococcal and candida mycoses.

  1971cited by this paper
• A pharmacologic guide to the clinical use of amphotericin B.

  1969cited by this paper
• In vitro studies with 5-fluorocytosine.

  1969cited by this paper
• Renal tubular acidosis due to amphotericin B.

  1968cited by this paper

• Synergistic Field Crop Pest Management Properties of Plant-Derived Essential Oils in Combination with Synthetic Pesticides and Bioactive Molecules: A Review

  2021cites this paper
• The idiosyncrasy of oropharyngeal yeast response to antifungal agents used as prophylaxis by HIV infected patients in South-Western Uganda.

  2021cites this paper
• Idiosyncratic response of yeasts, recovered from oropharyngeal lesions of HIV patients, to prophylactic antifungal agents, in South Western Uganda

  2019cites this paper
• Mini review: interactions between antifungal azoles, neurological bladder and urinary problems

  2019cites this paper
• Innovation of natural essential oil-loaded Orabase for local treatment of oral candidiasis

  2015cites this paper
• Formulations of deoxycholic for therapy: a patent review (2011 – 2014)

  2015cites this paper
• Studies on Ergosterol liquid membrane using Amphotericin B

  2013cites this paper
• Diarylamidines: high potency inhibitors of acid-sensing ion channels.

  2010cites this paper
• The Analysis of Antimicrobial Testing Vincetoxicum stocksii and Isolation of a Highly Active Compound Against Candida albicans by Using Various Different Techniques.

  2008cites this paper
• Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry.

  2008cites this paper
• Chemical combination effects predict connectivity in biological systems

  2007cites this paper
• Efficacies of caspofungin and a combination of caspofungin and meropenem in the treatment of murine disseminated candidiasis

  2006cites this paper
• COMPARATIVE ANALYSIS OF ANTIFUNGAL ACTIVITY OF NATURAL REMEDIES VERSUS MICONAZOLE NITRATE SALT AGAINST CANDIDA ALBICANS

  2005cites this paper
• Factors contributing to the increased prevalence of fungal infectionsa Increased Numbers of Immunocompromised Patients

  2005cites this paper
• Estructura y actividad de los antifúngicos

  2005cites this paper
• Evaluation of Disseminated Candidiasis by FTIR Spectroscopy

  2005cites this paper
• The life and death of sponge cells

  2004cites this paper
• Cerebral aspergillosis and encephalomeningocele

  2004cites this paper
• Flow cytometric assay for estimating fungicidal activity of Amphotericin B in human serum

  2004cites this paper
• Ultrastructural Morphometry of Renal Tubule Epithelium in Rats Treated with Conventional Amphotericin B Deoxycholate or Amphotericin B Colloidal Dispersion

  2004cites this paper
• Advances in Protein Chemistry, Volume 65: Proteome Characterization and Proteomics

  2004cites this paper
• Antifungals and their use in veterinary ophthalmology.

  2004cites this paper
• Systemic antifungal agents

  2003cites this paper
• Diagnosis and treatment of oropharyngeal candidiasis.

  2003cites this paper
• New agents for the treatment of systemic fungal infections – current status

  2002influential citation
• A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients.

  2002cites this paper
• Fungal infection in the lung transplant recipient

  2001cites this paper
• New agents for treatment of systemic fungal infections

  2000influential citation
• THIS ARTICLE HAS BEEN RETRACTED Hamycin treatment of candidiasis in normal and diabetic rats

  1999cites this paper
• Hamycin treatment of candidiasis in normal and diabetic rats.

  1999cites this paper
• Effect of biphenyl dimethyl dicarboxylate on the cellular and nonspecific immunosuppressions by ketoconazole in mice

  1999cites this paper
• Effect of biphenyl dimethyl dicarboxylate on the humoral immunosuppression by ketoconazole in mice

  1999cites this paper
• Amphotericin B Colloidal Dispersion

  1999cites this paper
• Antifungal agents. Part I. Amphotericin B preparations and flucytosine.

  1998cites this paper
• Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole

  1998cites this paper
• Oropharyngeal candidiasis: a review of its clinical spectrum and current therapies.

  1998cites this paper
• Transfusing platelets 2 h after the completion of amphotericin‐B decreases its detrimental effect on transfused platelet recovery and survival

  1998cites this paper
• Update on invasive candidiasis.

  1997cites this paper
• An audit of the use of antifungal agents.

  1996cites this paper
• Amphotericin B induced abnormalities in human platelets

  1996cites this paper
• Histoplasmosis--a ten year follow-up.

  1996cites this paper
• Fluconazole and Amphotericin B for Cryptococcal Meningitis

  1996cites this paper
• Antifungal prophylaxis with itraconazole in neutropenic patients: pharmacological, microbiological and clinical aspects

  1996cites this paper
• Itraconazole for the treatment of cryptococcosis in cats.

  1995cites this paper
• Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties.

  1995cites this paper
• Chemoprophylaxis for pulmonary aspergillosis during intensive chemotherapy.

  1994cites this paper
• Effect of amphotericin B and fluconazole on platelet membrane glycoproteins

  1994cites this paper
• The changing face of childhood meningitis.

  1994cites this paper
• Use of Antifungal Therapy in Hospitalized Patients I. Results Prior to the Marketing of Fluconazole

  1994cites this paper
• Candida Esophagitis in an Immunocompetent Pregnant Woman

  1993cites this paper
• Antifungal therapy: from amphotericin B to present.

  1993cites this paper
• SUPERFICIAL AND DEEP CANDIDOSIS

  1993cites this paper
• [Lesions of the lungs in hemoblastoses].

  1992cites this paper
• Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy.

  1992cites this paper
• Itraconazole in Antifungal Therapy

  1992cites this paper
• Espondilodiscitis y artritis de tobillo por Candida albicans en escolar

  1992cites this paper
• [Antibacterial therapy in polyclinic practice].

  1992cites this paper
• Rapid intravenous infusion of amphotericin B: a pilot study.

  1992cites this paper
• Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients.

  1991cites this paper
• Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections.

  1991cites this paper
• Dematiaceous Fungal Sinusitis

  1991cites this paper
• Update on antimicrobial agents.

  1991cites this paper
• Amphotericin B: 30 years of clinical experience.

  1990cites this paper
• Randomized, double-blind trial of 1- versus 4-hour amphotericin B infusion durations

  1990cites this paper
• Imidazoles and Triazoles in Antifungal Therapy

  1990cites this paper
• Nephrotoxicity of common drugs used by urologists.

  1990cites this paper
• Amphotericin B 2-morpholinoethylamide diaspartate, a new water soluble derivative of the antibiotic. Synthesis and biological properties.

  1990cites this paper
• Infectious agents and disease of peripheral nerve.

  1990cites this paper
• New therapeutic agents in veterinary dermatology.

  1990cites this paper
• Cryptococcosis in a renal unit.

  1990cites this paper
• Renal complications of human immunodeficiency virus type 1.

  1990cites this paper
• Evaluation of ketoconazole and itraconazole for treatment of disseminated cryptococcosis in cats.

  1990cites this paper
• Suppression of neutrophil and lymphoproliferative responses in vitro by itraconazole but not fluconazole.

  1990cites this paper
• Recently described feline dermatoses.

  1990cites this paper
• Effects of the newer antifungal agents (bifonazole, ICI 195, 739 and amorolfin) on in vitro phagocytic, lymphocytic and natural-killer cell responses.

  1989cites this paper
• 5-Fluorocytosine resistance in clinical isolates of Cryptococcus neoformans.

  1989cites this paper
• Pulmonary Infections Due to Higher Bacteria and Fungi in the Immunocompromised Host

  1989cites this paper
• Stereotactic drainage of Aspergillus brain abscess with long-term survival: case report and review.

  1989cites this paper
• Chronic cavitary histoplasmosis. Failure of oral treatment with ketoconazole.

  1989cites this paper
• Liposomes as Carriers of Antifungal Drugs

  1988cites this paper
• Invasive Nasal Alternariosis

  1988cites this paper
• Amides of polyene macrolide aureofacin. Synthesis and biological properties.

  1987cites this paper
• Antifungal agents used for deep-seated mycotic infections.

  1987cites this paper
• Miconazol und saprophytische Mikromyzeten: Miconazole and Saprophytic Micromycetes

  1986cites this paper
• Amphotericin—How Safe and Effective?

  1985influential citation
• Lokaltherapie des Lungenaspergilloms‐Versuch einer endobronchialen Behandlung/Topical Therapy of Aspergilloma of the Lung—A Trial of Endobronchial Treatment

  1983cites this paper